Semaglutide’s heart signal keeps getting bigger—and the access story underneath it may be getting shakier. This is GLP-1 Daily. Today: what the science means, where the supply chain just tightened, and whether Medicare access has an expiration date. First up, the heart data—and why it’s getting harder to call these drugs weight loss alone. EurekAlert! writes:
Researchers examined known risk factors for heart disease, such as body weight and waist circumference, in patients taking part in a clinical trial of semaglutide for overweight and obesity. Although the risk of serious cardiovascular disease was lower for those taking the drug, only half of this reduction could be explained by changes in these risk factors.
SELECT had 17,604 people, and semaglutide cut serious cardiovascular events by 20%. This European Heart Journal analysis says changes in weight and waist explained only about half that benefit. Which makes the old insurer line—“it’s just a weight-loss drug”—look even more dated. The evidence is moving; prior-auth forms need to catch up. Careful, though: “the other half” isn’t a license to invent a mechanism. It leaves cardiology with a real unanswered question—whether it’s vascular inflammation, plaque biology, or something else—and we need the research, not the marketing. And it should change the coverage conversation now. A patient with obesity and established cardiovascular disease shouldn’t have to prove this drug matters only if the scale moves fast enough. Here's BigGo:
Sinopep's wholly-owned subsidiary Chengdu Sinopep Biopharmaceutical was placed on the FDA's Import Alert 66-40 list on September 19, prompting the company to announce a complete halt of all peptide active pharmaceutical ingredient (API) sales and shipments to the US market until the alert is lifted. The ban stems from eight observations documented in a Form FDA 483 issued after an on-site inspection in August, covering critical quality attribute identification, contamination control capabilities, and quality system governance.
Sinopep’s U.S. peptide API shipments are frozen after the FDA put its Chengdu subsidiary on Import Alert 66-40 on September 19. For anyone getting compounded peptides, this is the part of the supply chain that can disappear before a pharmacy ever gets the ingredient. And let’s be precise: eight Form 483 observations after an August inspection covered contamination control and identifying critical quality attributes. Those are manufacturing fundamentals, not some minor paperwork squabble. Sinopep says U.S. sales were 167 million yuan in the first half of 2026—almost a third of its revenue. So yes, it has every incentive to fix this fast. But patients need more than a supplier’s incentive; they need an access system that doesn’t rest on one fragile overseas API pipeline. The stock fell 18.61% on the news. Markets saw the risk immediately. Patients deserve that same clarity about where the ingredients in their medication come from. Here's AllSci:
In the Phase III REIMAGINE 5 trial, CagriSema 1.0 mg/1.0 mg achieved estimated average weight loss of 12.4% versus 9.1% for tirzepatide 5 mg at week 60 in adults with type 2 diabetes inadequately controlled on metformin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, or both — meeting the primary superiority endpoint on weight. HbA1c reduction was 1.71% versus 1.67%, meeting the non-inferiority co-primary endpoint.
Novo says CagriSema delivered 12.4% weight loss at 60 weeks, versus 9.1% for tirzepatide. Before anyone takes a victory lap: that tirzepatide arm was 5 milligrams. Right—and Novo already has the less flattering comparison: CagriSema at 2.4/2.4 missed non-inferiority against tirzepatide 15 milligrams, 23.0% to 25.5%. Dose selection changes the headline. REDEFINE 9 is the cleaner read: Novo reports 21.0% weight loss versus 2.0% on placebo at week 68. Solid Phase III result, with an FDA obesity decision expected in Q4—but the supportive blood-pressure and lipid numbers still weren’t disclosed. And when this reaches formulary meetings, watch them celebrate the mechanism—semaglutide plus an amylin analogue—then make patients clear the same old prior-auth obstacle course. Stephanie Cruz, writing in IBTimes UK:
Access comes through a temporary federal scheme called the Medicare GLP-1 Bridge. Seniors who enrol pay a copay of $50 (£37) a month, and the manufacturers supply the drugs at a net price of $245 (£183) a month. That leaves about $195 (£146) per patient each month for Medicare, and therefore taxpayers, to cover.
Seven hundred thousand seniors enrolled since July 1 is a big number. But it came from Lilly CEO David Ricks on CNBC, and 70% going to Lilly is also a very nice market-share statistic for the person delivering it. The $50 copay is the headline-friendly part. Medicare pays about $195 a month per patient under this Bridge program, which runs only through the end of 2027. “Temporary” needs to be said at full volume. You enroll 700,000 people in treatment, then put an end date on the access pathway—patients have seen this movie before. And after the SELECT analysis we just covered, payers have even less cover for treating these as cosmetic drugs. Whether that changes a prior-auth form before 2027? I’m not taking bets yet. Greg Slabodkin, writing in Pharma Manufacturing:
CEO Mike Doustdar said Novo aims to reach more than 60 million patients globally by 2030 and scale up manufacturing tenfold to supply 15 million patients with oral obesity therapies by the end of the decade, as the company faces looming patent expirations for semaglutide — the active ingredient in Ozempic and Wegovy — in the early 2030s.
Novo says it wants oral GLP-1 capacity for 15 million obesity patients by 2030—a tenfold jump from today’s levels. Big target, Mike Doustdar. Now show the manufacturing ramp, not just the Capital Markets Day slide. And 15 million globally sounds enormous until you put it next to Novo’s stated goal of reaching 60 million patients overall. That leaves four people outside the oral-therapy bucket for every one in it—and none of that tells us who can afford the prescription. The $9 billion API facility in Kalundborg is the detail I’m watching. We just talked about an FDA import alert at a peptide supplier; building more controlled capacity matters. It can prevent a shortage, but it can’t by itself prevent a prior-auth denial. Exactly. A pill that exists at industrial scale is still out of reach if the plan puts it on a specialty tier with a deductible the size of rent. If your team needs a daily briefing on your own industry, Lantern makes private versions like this one—covering your competitors, market, or beat, delivered to a private feed for your whole team. Learn more at lantern podcasts dot com slash briefings, with a 14-day free trial.
We’re watching for Novo’s expected U.S. regulatory decision on CagriSema’s obesity indication in Q4 2026, and for the Medicare GLP-1 Bridge programme, which is set to run through the end of 2027.
Links to every story are in the show notes, so take a look at the ones you want to explore further. That’s GLP-1 Daily for today. We’ll be back tomorrow. This is a Lantern Podcast.